TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01712789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
Study: NCT00072163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study: NCT04592133

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Ultrasonography Examination
Study: NCT00445055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol
Description: Intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Droperidol
Description: Intravenous injection
Study: NCT00632034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD34+ haemopoietic stem cells
Description: Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
Study: NCT00813956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine plus carboplatin plus BSI-201
Description: iv, 3 week cycles
Study: NCT04254237

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraumbilical Hasson trocar incision
Description: Infraumbilical Hasson trocar incision
Study: NCT02246374

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ExAblate Transcranial System
Description: ExAblate Transcranial System subthalamotomy for symptoms of Parkinson's Disease

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial System
Description: ExAblate Transcranial System subthalamotomy for symptoms of Parkinson's Disease
Study: NCT03891680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Injectable Product
Description: Intra articular Botox injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequancy
Description: Genicular nerves radiofrequancy
Study: NCT03548311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylcobalamin
Description: Patients receive methylcobalamin 50mg intramuscular injection twice a week.
Study: NCT04254237

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Supraumbilical Hasson trocar incision
Description: Supraumbilical Hasson trocar incision
Study: NCT03434132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or robotic radical cystectomy
Description: ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open or robotic radical cystectomy
Description: ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed.
Study: NCT01797432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
Description: Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane
Description: Intralesional injections of 2mLs of Restylane on one side of the scalp
Study: NCT03548311

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Patients receive saline solution intramuscular injection twice a week.
Study: NCT01693939

Intervention type: DEVICE
Group type: OTHER
Intervention: FS200 Femtosecond Laser
Study: NCT02967211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (U300)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine (U100)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT01850966

Intervention type: DRUG
Intervention: Iguratimod
Description: The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.
Study: NCT02216422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/Paritaprevir/Ritonavir
Description: Tablet; paritaprevir co-formulated with ritonavir and ombitasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet
Study: NCT01325987

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Subjects with vitamin D deficiency (serum 25(OH)D \<20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 1. group: vitamin D2 50000 IU weekly once for 8 weeks~2. nd group: placebo weekly once for 8 weeks
Study: NCT02341534

Intervention type: DEVICE
Group type: OTHER
Intervention: BioMonitor
Description: Patients will be implanted with the BioMonitor + Home Monitoring feature
Study: NCT02677103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial extracorporeal shock wave therapy
Description: he RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided needle puncture
Description: After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RSWT and USNP
Description: each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs.
Study: NCT03504865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Given at the end of the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard bupivacaine
Description: Given at the end of the operation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be administered as the placebo and will be given at the end of the operation.
Study: NCT02460744

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Description: Radiation dose of 34Gy in 10 fractions over 2 weeks.
Study: NCT00747981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic CT Scan
Description: Perform a CT Scan and an endoscopy
Study: NCT02986828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study: NCT03596983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Week 2 Intervention
Description: * Sleep Diaries (Daily)~* Phone Calls (weekly with study team)~* Wrist Accelerometry and fitbit 24/7 for 14 days~* SAFTEE Questionnaire~* ASA24~* Behavioral risk factor surveillance system (smoking and alcohol use questions)~* Psychological well-being (SF36)~* Index of Self Regulation~* PROMIS fatigue scale-morning (weekly)~* PROMIS fatigue scale-evening (weekly)~* Epworth Sleepiness Scale (weekly)
Study: NCT04503642

Intervention type: PROCEDURE
Intervention: Changing the surgical team for wound closure
Description: The intervention consists of the exchange of the primary surgical team with a second surgical team that consists of one surgeon and one student. The first surgical team then may leave the operation theatre but is continuously accessible for questions.
Study: NCT02986828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study: NCT03066388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse pressure variations
Description: Stroke volume and, pulse pressure variations obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin.
Study: NCT03533491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rewire App
Description: A prototype Rewire app will be designed and created; the first four modules will be evaluated by 60 high-risk adolescents. The teens are asked to complete each module and spend a few minutes each day for two weeks using the practice exercises.
Study: NCT03731585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in psychological sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in educational sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Participate in group sessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Participate in group sessions
Study: NCT03702738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: NAC is listed by WHO as an essential medicine for its use in paracetamol (acetaminophen) poisoning, in which it protects against fatal liver injury. It also reduces the viscosity of sputum, thereby serving as an expectorant.
Study: NCT03964909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging
Description: Undergo fMRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo CVR MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resting State Functional Connectivity Magnetic Resonance Imaging
Description: Undergo rs-fMRI
Study: NCT03912753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comunică
Description: Comunică is based on the Information-Motivation-Behavioral Skills (IMB) model of health behavior change, which postulates that individuals must possess the requisite information for enacting sexual health, motivation to change their HIV risk and alcohol use, and behavioral skills necessary for reducing their risk. Therefore, Comunică includes MI to provide accurate information about HIV transmission, alcohol abuse, and local GBM-affirmative health resources and build motivation to improve behavioral skills (via CBST). CBST is a therapeutic approach used in the treatment of various behavioral problems, such as alcohol abuse and depression and more recently HIV risk. CBST can help modify cognitions driving unhealthy behaviors, promote awareness of contextual triggers and unhealthy behavioral patterns, and teach coping skills to improve health. Comunică also draws upon minority stress theory recognizing that stigmatizing societal contexts compromise health behavior.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Attention Control
Description: The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.
Study: NCT02025205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial Valve
Description: Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
Study: NCT04575675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Sacubitril-Valsartan, maximal tolerated dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sacubitril-Valsartan
Description: Sacubitril-Valsartan, maximal tolerated dosage
Study: NCT02831920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI and targeted biopsies
Study: NCT02364531

Intervention type: OTHER
Intervention: Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry
Description: Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
Study: NCT04168307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle trainer device
Description: The ankle trainer provides passive stretch in dorsal flexion of the ankle as well as active plantar flexion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: The patients were instructed in stretching exercises using a non-elastic band
Study: NCT02611362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB Gaming Intervention
Study: NCT05444205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text4Baby or Bright by Text Referral
Description: Passive texting programs where participants receive free text messages on topics such as child development and parenting tips three times per week. Text4Baby serves parents of children under one year. Bright by Text serves parents of children under eight years of age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurture Program Warm Referral
Description: Nurture Program is a nonprofit organization that promotes healthy development in young children by pairing moms with experienced and knowledgeable mentors who use text messaging to answer questions and provide helpful information, while offering support and encouragement throughout the child's first few years of life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurture Program Warm Referral
Description: Nurture Program is a nonprofit organization that promotes healthy development in young children by pairing moms with experienced and knowledgeable mentors who use text messaging to answer questions and provide helpful information, while offering support and encouragement throughout the child's first few years of life.
Study: NCT04575675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol
Study: NCT03567499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.
Study: NCT04575675

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beta blocker
Description: Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid Receptor Antagonist
Description: Mineralocorticoid receptor antagonist, including spironolactone or eplerenone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mineralocorticoid Receptor Antagonist
Description: Mineralocorticoid receptor antagonist, including spironolactone or eplerenone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy and/or implantable cardioverter defibrillator
Description: CRT-P, CRT-D or ICD if clinically indicated

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac resynchronization therapy and/or implantable cardioverter defibrillator
Description: CRT-P, CRT-D or ICD if clinically indicated
Study: NCT01782326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
Description: Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
Study: NCT01720017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preclinical Manikin Training
Description: During the preclinical manikin training, each subject will perform 10 intubations in a manikin with a difficult airway simulated by swelling the manikin tongue and placing it in a cervical collar.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inservice Training
Description: Inservice training will include review of a product information handout and a video demonstration.
Study: NCT04437771

Intervention type: OTHER
Intervention: Safety and efficacy assessments
Description: Long term disease and gene therapy specific safety evaluations and efficacy assessments
Study: NCT02298543

Intervention type: OTHER
Intervention: coronary spasm
Study: NCT03567499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.